ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO353

Comparison of Therapeutic Effects of Adipose- and Bone Marrow-Derived Mesenchymal Stem Cells on Renal Fibrosis

Session Information

Category: Development, Stem Cells, and Regenerative Medicine

  • 600 Development, Stem Cells, and Regenerative Medicine

Authors

  • Yoshida, Maria, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima, Japan
  • Nakashima, Ayumu, Yamanashi Daigaku Igakubu Fuzoku Byoin, Chuo, Yamanashi, Japan
  • Ishiuchi, Naoki, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima, Japan
  • Miyasako, Kisho, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima, Japan
  • Tanaka, Yoshiki, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima, Japan
  • Morimoto, Keisuke, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima, Japan
  • Sasaki, Kensuke, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima, Japan
  • Masaki, Takao, Hiroshima Daigaku Byoin, Hiroshima, Hiroshima, Japan
Background

Mesenchymal stem cells (MSCs) have garnered strong interest as a therapeutic tool for renal fibrosis. Although both adipose-derived and bone marrow-derived MSCs (ADSCs and BMSCs, respectively) suppress renal fibrosis, which of these two has a stronger therapeutic effect remains unclear. This study aimed to compare the antifibrotic effects of ADSCs and BMSCs from the same rats.

Methods

ADSCs and BMSCs were extracted from adipose tissue and bone marrow from same rats and cultured in serum-containing and serum-free medium, respectively. After renal ischemia-reperfusion injury, ADSCs and BMSCs were injected through the abdominal aorta. At 21 days post-injection, the rats were sacrificed, and their kidneys were analyzed. Next, ADSCs and BMSCs were infused into mice via tail vein, and 24h survival rate and pulmonary emboli were analyzed. In in vitro experiments, we compared the procoagulation factors and humoral factors in ADSCs and BMSCs.

Results

When cultured in serum-containing medium, ADSCs had a more potent inhibitory effect than BMSCs on renal fibrosis induced by ischemia-reperfusion injury in rats. ADSCs and BMSCs cultured in serum-free medium were equally effective in suppressing renal fibrosis. Mice infused with ADSCs (serum-containing or serum-free cultivation) had a higher death rate from pulmonary embolism than those infused with BMSCs. In vitro, mRNA levels of tissue factor, tumor necrosis factor-α-induced protein 6 and prostaglandin E synthase were higher in ADSCs than BMSCs, while that of vascular endothelial growth factor was higher in BMSCs than ADSCs. Although ADSCs had a stronger antifibrotic effect, these findings support the consideration of thromboembolism risk in clinical applications.

Conclusion

Our results emphasize the importance of deciding between ADSCs and BMSCs based upon the target disease and culture method.

Funding

  • Government Support – Non-U.S.